JP Morgan Chase
CMPX icon

JP Morgan Chase’s Compass Therapeutics CMPX Stock Holding History

JP Morgan Chase’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Sell
789,399
-58,303
-7% -$172K ﹤0.01% 4304
2026
Q1 		$4.32M Sell
847,702
-22,312
-3% -$129K ﹤0.01% 3456
2025
Q4 		$4.67M Sell
870,014
-1,129,264
-56% -$5.21M ﹤0.01% 3372
2025
Q3 		$7M Sell
1,999,278
-126,439
-6% -$399K ﹤0.01% 3061
2025
Q2 		$5.53M Sell
2,125,717
-59,763
-3% -$123K ﹤0.01% 3062
2025
Q1 		$4.15M Buy
2,185,480
+1,913,152
+703% +$5.09M ﹤0.01% 3319
2024
Q4 		$395K Buy
272,328
+227,864
+512% +$378K ﹤0.01% 5159
2024
Q3 		$81.8K Sell
44,464
-1,419
-3% -$1.77K ﹤0.01% 5777
2024
Q2 		$45.9K Buy
45,883
+7,530
+20% +$11K ﹤0.01% 5890
2024
Q1 		$75.9K Sell
38,353
-23,979
-38% -$41.4K ﹤0.01% 5784
2023
Q4 		$97.2K Sell
62,332
-407
-0.6% -$704 ﹤0.01% 5743
2023
Q3 		$124K Sell
62,739
-8,425
-12% -$20.8K ﹤0.01% 5351
2023
Q2 		$226K Buy
71,164
+70,757
+17,385% +$222K ﹤0.01% 5007
2023
Q1 		$1K Buy
+407
New +$1.6K ﹤0.01% 6501
2022
Q1 		– Sell
-23,749
Closed -$75K – 6634
2021
Q4 		$75K Buy
+23,749
New +$78.8K ﹤0.01% 5788

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase's CMPX Position: Q2 2026 in Review

JP Morgan Chase reduced its Compass Therapeutics (CMPX) stake by 6.9% in Q2 2026, selling an estimated $172K and leaving 789,399 shares worth $1.71M. The position accounts for ﹤0.01% of the portfolio, ranked #4304.

JP Morgan Chase first reported a position in CMPX in Q4 2021 and has held it in 15 quarters since. The position peaked at $7M in Q3 2025. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • JP Morgan Chase held 789,399 shares of Compass Therapeutics worth $1.71M as of Q2 2026.
  • JP Morgan Chase sold 58,303 Compass Therapeutics shares in Q2 2026, an estimated $172K.
  • Compass Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4304 holding.
  • JP Morgan Chase first reported a position in Compass Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • JP Morgan Chase's Compass Therapeutics position peaked at $7M in Q3 2025.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.